Rezolute will host a virtual investor event on November 10, 2025, to discuss ersodetug's clinical development and market opportunities.
Quiver AI Summary
Rezolute, Inc. will hold a virtual investor event on November 10, 2025, focusing on the market potential and clinical development of its treatment, ersodetug, which is being tested in Phase 3 trials for congenital hyperinsulinism and tumor hyperinsulinism. Sunil Karnawat, the Chief Commercial Officer, will outline the commercial prospects of ersodetug, and the management will discuss ongoing clinical programs, including the sunRIZE study, with topline results expected in December 2025. Notable hyperinsulinism experts will also participate, addressing the unmet medical needs and treatment options for these conditions. The event will be accessible via phone and webcast, with a replay available afterward. Ersodetug is a fully human monoclonal antibody aiming to mitigate hypoglycemia by reducing insulin receptor over-activation.
Potential Positives
- Rezolute will host a virtual investor event to discuss the market opportunity and clinical development of ersodetug, showcasing their commitment to transparency and engagement with investors.
- The event will feature insights from leading experts in the field of hyperinsulinism, enhancing the credibility of Rezolute's initiatives and providing valuable perspectives on the unmet medical need.
- Rezolute is conducting two Phase 3 studies for ersodetug, indicating significant progress in their drug development pipeline and commitment to addressing rare diseases.
- Topline results for the Phase 3 sunRIZE study are expected in December 2025, which could be a significant milestone for the company and its investors.
Potential Negatives
- The announcement that topline results for the Phase 3 sunRIZE study will not be available until December 2025 may raise concerns about the timeline and progress of their clinical development.
- As a late-stage company focused on rare diseases, any delay or uncertainty in clinical results could negatively impact investor confidence and stock performance.
- There is significant emphasis on the unmet medical need, which might suggest that existing treatments are inadequate, potentially questioning the viability and readiness of Rezolute's solution in the market.
FAQ
What is the purpose of Rezolute's virtual investor event?
The event will highlight the market opportunity and clinical development of ersodetug for treating hyperinsulinism.
When will the investor event take place?
The virtual investor event is scheduled for November 10, 2025, from 12:00 to 1:30 pm EST.
Who will be presenting at the Rezolute investor event?
Presenters include Rezolute's Chief Commercial Officer, Sunil Karnawat, and leading hyperinsulinism experts, Dr. Mansa Krishnamurthy and Dr. Azeez Farooki.
How can I access the live webcast of the event?
The live webcast can be accessed through the investor page on Rezolute’s website at https://ir.rezolutebio.com.
What is ersodetug and its significance?
Ersodetug is a fully human monoclonal antibody aimed at reducing hypoglycemia caused by various forms of hyperinsulinism.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RZLT Insider Trading Activity
$RZLT insiders have traded $RZLT stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RZLT stock by insiders over the last 6 months:
- YOUNG-JIN KIM purchased 1,230,769 shares for an estimated $3,999,999
- DARON EVANS (CFO) has made 2 purchases buying 15,549 shares for an estimated $73,416 and 0 sales.
- BRIAN KENNETH ROBERTS (Chief Medical Officer) purchased 2,500 shares for an estimated $10,939
- NERISSA KREHER purchased 3,076 shares for an estimated $9,997
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RZLT Hedge Fund Activity
We have seen 80 institutional investors add shares of $RZLT stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,304,158 shares (+96.9%) to their portfolio in Q2 2025, for an estimated $28,116,544
- BLACKROCK, INC. added 3,634,224 shares (+812.5%) to their portfolio in Q2 2025, for an estimated $16,208,639
- UBS GROUP AG added 2,420,653 shares (+392.6%) to their portfolio in Q2 2025, for an estimated $10,796,112
- MANGROVE PARTNERS IM, LLC added 2,297,489 shares (+inf%) to their portfolio in Q2 2025, for an estimated $10,246,800
- GREAT POINT PARTNERS LLC added 2,200,420 shares (+264.1%) to their portfolio in Q2 2025, for an estimated $9,813,873
- BLACKSTONE INC. added 1,815,549 shares (+104.1%) to their portfolio in Q2 2025, for an estimated $8,097,348
- ROSALIND ADVISORS, INC. added 1,741,211 shares (+inf%) to their portfolio in Q2 2025, for an estimated $7,765,801
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RZLT Analyst Ratings
Wall Street analysts have issued reports on $RZLT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 09/22/2025
- BTIG issued a "Buy" rating on 09/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for $RZLT, check out Quiver Quantitative's $RZLT forecast page.
$RZLT Price Targets
Multiple analysts have issued price targets for $RZLT recently. We have seen 5 analysts offer price targets for $RZLT in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Jason N. Butler from Citizens set a target price of $17.0 on 10/29/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $15.0 on 09/22/2025
- Jason McCarthy from Maxim Group set a target price of $20.0 on 09/19/2025
- Julian Harrison from BTIG set a target price of $17.0 on 09/18/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $14.0 on 09/03/2025
Full Release
REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the company will host a virtual investor event via webcast on Monday, November 10, 2025, from 12:00 – 1:30 pm EST. The event will highlight the market opportunity and clinical development of ersodetug, which is currently being evaluated in two Phase 3 studies in congenital hyperinsulinism (HI) and tumor HI, respectively.
During the event, Rezolute Chief Commercial Officer, Sunil Karnawat, will discuss the anticipated commercial opportunities for ersodetug as a potential treatment for congenital and tumor HI. In addition, Rezolute management will review the Company’s ongoing clinical development programs, including the Phase 3 sunRIZE study in congenital HI, with topline results expected in December 2025, and the Phase 3 upLIFT study in tumor HI.
The call will also feature remarks from two leading hyperinsulinism experts:
- Mansa Krishnamurthy, MD, Pediatric Endocrinologist, Cincinnati Children’s Hospital Medical Center and Assistant Professor, Department of Pediatrics, University of Cincinnati
- Azeez Farooki, MD, Attending Physician and Clinical Member, Endocrinology Service, Memorial Sloan Kettering Cancer Center and Associate Clinical Professor, Weill Cornell Medical College
The physicians will discuss the significant unmet medical need, patient profiles, and current treatment landscape for each indication.
Conference Call Information
To access the event by phone, please dial 1-877-317-6789 from the U.S. and Canada or 1-412-317-6789 internationally and ask to be joined into the Rezolute call. The live webcast can be accessed on the investor page of Rezolute’s website at https://ir.rezolutebio.com. A replay of the webcast will be available approximately two hours after the completion of the event.
About Ersodetug
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.
Rezolute Contacts:
Christen Baglaneas
[email protected]
508-272-6717
Carrie McKim
[email protected]
336-608-9706
